论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
利用 EVs-ncRNA 治疗肺癌:从致癌途径到新型诊断和治疗策略
Authors Shi Y, Chen H, Li W, An S, Li L, Gao H
Received 13 March 2025
Accepted for publication 9 July 2025
Published 14 July 2025 Volume 2025:20 Pages 9031—9054
DOI https://doi.org/10.2147/IJN.S528115
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Professor Jie Huang
Yuqing Shi, Hong Chen, Wei Li, Song An, Linfang Li, Hongmei Gao
Department of Respiratory Medicine, Shenyang 10th People’s Hospital, Shenyang Chest Hospital, Shenyang, 110044, People’s Republic of China
Correspondence: Hongmei Gao, Email gaohongmei1974@163.com
Abstract: Extracellular vesicles (EVs), serving as pivotal mediators of intercellular communication within the tumor microenvironment (TME), exert substantial regulatory influence on lung cancer progression and treatment resistance through their cargo of non-coding RNA (ncRNA). This comprehensive review systematically delineates the biogenesis mechanisms of EVs-ncRNA and their dualistic biological functions in lung carcinogenesis. Pro-tumoral ncRNA are selectively packaged into EVs through specialized sorting mechanisms, subsequently activating oncogenic pathways to potentiate tumor proliferation, invasion, and angiogenesis. Conversely, tumor-suppressive ncRNA are depleted intracellularly via EV-mediated export, thereby attenuating their regulatory control over tumor-suppressive pathways. Notably, EVs-ncRNA derived from tumor stromal components—CAFs, TAMs and BMSCs—orchestrate immunosuppressive reprogramming through cross-regulatory networks, facilitating M2 macrophage polarization, T-cell exhaustion, and consequent therapeutic resistance. Clinically, EVs-ncRNA hold substantial promise as multifaceted biomarkers, enabling early detection, prognostic stratification, and dynamic monitoring of therapy resistance in malignancies. Moreover, their emerging roles as therapeutic carriers or molecular targets highlight transformative potential in precision oncology. Nevertheless, critical challenges persist, including heterogeneity resolution among EVs-ncRNA subpopulations, standardization of cross-species engineered EV production, and establishment of multi-omics dynamic monitoring systems. This synthesis provides a molecular foundation and translational framework for developing innovative diagnostic and therapeutic strategies in lung cancer management.
Keywords: EVs, exosome, ncRNA, lung cancer, NSCLC, TME